BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 26842166)

  • 1. Pattern of infection, therapy, outcome and risk stratification of patients with febrile neutropenia in a tertiary care oncology hospital in India.
    Noronha V; Joshi A; Patil VM; Bhosale B; Muddu VK; Banavali S; Kelkar R; Prabhash K
    Indian J Cancer; 2014; 51(4):470-4. PubMed ID: 26842166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An audit of febrile neutropenia cases from a rural cancer center in India.
    Patil VM; Chakarborty S; Kumar MS; Geetha M; Dev S; Samuel S; Ahmed G; Nayanar SK; Vineetha R; Nair CK
    Indian J Cancer; 2014; 51(4):487-90. PubMed ID: 26842173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of febrile neutropenia in malignancy using the MASCC score and other factors: Feasibility and safety in routine clinical practice.
    Kumar P; Bajpai J; Shetty N; Medekar A; Kurkure PA; Ghadyalpatil N; Gupta S; Noronha V; Kanujia A; Parikh P; Banavali SD
    Indian J Cancer; 2014; 51(4):491-5. PubMed ID: 26842174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors predicting outcome in high risk febrile neutropenia in patients receiving intensive chemotherapy for acute sleukemia: A prospective, observational study from South India.
    Rajendranath R; Balasubramaniyum VK; Vijayakumar V; Ganesan P; Tenali GS
    Indian J Cancer; 2014; 51(4):481-6. PubMed ID: 26842171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemotherapy-induced febrile neutropenia: About 186 episodes. Clinical, microbiological and therapeutic characteristics].
    Masmoudi S; Khanfir A; Maalej-Mezghan S; Hammami A; Frikha M
    Tunis Med; 2015 Apr; 93(4):217-22. PubMed ID: 26375737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third generation cephalosporin resistant Enterobacteriaceae and multidrug resistant gram-negative bacteria causing bacteremia in febrile neutropenia adult cancer patients in Lebanon, broad spectrum antibiotics use as a major risk factor, and correlation with poor prognosis.
    Moghnieh R; Estaitieh N; Mugharbil A; Jisr T; Abdallah DI; Ziade F; Sinno L; Ibrahim A
    Front Cell Infect Microbiol; 2015; 5():11. PubMed ID: 25729741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice.
    Innes H; Lim SL; Hall A; Chan SY; Bhalla N; Marshall E
    Support Care Cancer; 2008 May; 16(5):485-91. PubMed ID: 17899215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Modalities of management of cancer patients with febrile neutropenia in the oncology emergency unit of Gustave-Roussy and their related costs].
    Borget I; Antoun S; Chachaty E; Gachot B; Alibay A; Di Palma M; Merad M
    Bull Cancer; 2014 Oct; 101(10):925-31. PubMed ID: 25373692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and microbiological profile of febrile neutropenia in solid tumors and hematological malignancies at a tertiary cancer care center in South India.
    Jacob LA; Lakshmaiah KC; Govindbabu K; Suresh TM; Lokanatha D; Sinha M; Vijaykumar BR; Sumathi BG; Jayashree RS
    Indian J Cancer; 2014; 51(4):464-8. PubMed ID: 26842163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk predictors for adverse outcome in pediatric febrile neutropenia: Single center experience from a low and middle-income country.
    Prasad M; Chinnaswamy G; Arora B; Vora T; Hawaldar R; Banavali S
    Indian J Cancer; 2014; 51(4):432-7. PubMed ID: 26842150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Febrile neutropenia in the tropics: a description of clinical and microbiological findings and their impact on inappropriate therapy currently used at an oncological reference center in Colombia.
    Cortés JA; Cuervo S; Gómez CA; Bermúdez D; Martínez T; Arroyo P
    Biomedica; 2013; 33(1):70-7. PubMed ID: 23715309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pattern of bloodstream infections in patients with hematological malignancies in a tertiary care centre.
    Bansal S; Advani SH
    Indian J Cancer; 2014; 51(4):447-9. PubMed ID: 26842155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
    Sipahi OR; Arda B; Nazli-Zeka A; Pullukcu H; Tasbakan M; Yamazhan T; Ozkoren-Calik S; Sipahi H; Ulusoy S
    Int J Clin Pract; 2014 Feb; 68(2):230-5. PubMed ID: 24372736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors associated with complications in patients with chemotherapy-induced febrile neutropenia in emergency department.
    Lynn JJ; Chen KF; Weng YM; Chiu TF
    Hematol Oncol; 2013 Dec; 31(4):189-96. PubMed ID: 23303687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urine cultures at the onset of febrile neutropenia rarely impact antibiotic management in asymptomatic adult cancer patients.
    Grigg SE; Date P; Loh Z; Estacio O; Johnson DF; Hawkes EA; Grigg A
    Support Care Cancer; 2019 Apr; 27(4):1223-1227. PubMed ID: 30259115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score.
    Uys A; Rapoport BL; Anderson R
    Support Care Cancer; 2004 Aug; 12(8):555-60. PubMed ID: 15197637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.
    Weycker D; Barron R; Kartashov A; Legg J; Lyman GH
    J Oncol Pharm Pract; 2014 Jun; 20(3):190-8. PubMed ID: 23824496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for refractory febrile neutropenia in urological chemotherapy.
    Yasufuku T; Shigemura K; Tanaka K; Arakawa S; Miyake H; Fujisawa M
    J Infect Chemother; 2013 Apr; 19(2):211-6. PubMed ID: 23011233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and source of infection in cancer patients with febrile neutropenia: an experience from a developing country.
    Joudeh N; Sawafta E; Abu Taha A; Hamed Allah M; Amer R; Odeh RY; Salameh H; Sabateen A; Aiesh BM; Zyoud SH
    BMC Infect Dis; 2023 Feb; 23(1):106. PubMed ID: 36814229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.